Insights into mechanisms of graft-versus-host disease through humanised mouse models A Elhage, C Sligar, P Cuthbertson, D Watson, R Sluyter Bioscience reports 42 (9), BSR20211986, 2022 | 13 | 2022 |
Post‐transplant cyclophosphamide limits reactive donor T cells and delays the development of graft‐versus‐host disease in a humanized mouse model SR Adhikary, P Cuthbertson, L Nicholson, KM Bird, C Sligar, M Hu, ... Immunology 164 (2), 332-347, 2021 | 8 | 2021 |
Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐versus‐host disease development in humanized mice treated with post … C Sligar, P Cuthbertson, NA Miles, SR Adhikary, A Elhage, G Zhang, ... Immunology and Cell Biology 101 (7), 639-656, 2023 | 6 | 2023 |
Purinergic signalling in graft-versus-host disease R Sluyter, P Cuthbertson, A Elhage, C Sligar, D Watson Current Opinion in Pharmacology 68, 102346, 2023 | 6 | 2023 |
Humanized mouse model to study the P2X7 receptor in graft-versus-host disease D Watson, SR Adhikary, P Cuthbertson, NJ Geraghty, KM Bird, A Elhage, ... The P2X7 Receptor: Methods and Protocols, 315-340, 2022 | 4 | 2022 |
A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice A Elhage, P Cuthbertson, C Sligar, D Watson, R Sluyter Pharmaceutics 15 (9), 2263, 2023 | 2 | 2023 |
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice P Cuthbertson, A Button, C Sligar, A Elhage, KL Vine, D Watson, R Sluyter International Journal of Molecular Sciences 25 (3), 1775, 2024 | 1 | 2024 |
Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice C Sligar, E Reilly, P Cuthbertson, KL Vine, KM Bird, A Elhage, ... Clinical & Translational Immunology 13 (3), e1497, 2024 | | 2024 |